Please assess the completion status of the following clinical trial:

Trial Title: Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have read the Information for the Patient and signed the Informed Consent Form.~* Diagnosis of active ulcerative colitis since at least 4 weeks as confirmed endoscopically and histologically.~* Disease Activity Index comprised between 3 and 6, inclusive (mild ulcerative colitis), with rectal bleeding sub-score of at least 1.~* Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine standard therapy for greater than or equal to 4 weeks prior to screening assessments.~* If female, not pregnant or nursing. For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 4 weeks from the last dose of drug and utilization of an efficient method of birth control for the entire duration of the trial and until the first menses after a 30-day period after the last dose of trial medication.~Exclusion Criteria:~* Crohn's disease and indeterminate colitis.~* Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.~* Use of systemic antibiotics in the last 10 days preceding the screening.~* Use of systemic Nonsteroidal anti-inflammatory drugs on a repeat basis in the last 10 days preceding the screening.~* Use of probiotics started within 10 days preceding the screening. A stable regimen from at least 10 days prior to screening is allowed but the patient must be willing to continue up to the end of the study.~* Use of immunosuppressants or biological agents within the last 6 weeks preceding the screening.~* Treatment with L-carnitine or its esters derivatives within the last 3 months.~* Stool culture positive for enteric pathogens (eg, Shigella, Salmonella, Yersinia, Campylobacter) or toxins (C.difficile).~* Significantly impaired liver, renal, pulmonary or cardiovascular function as assessed by the investigator.~* History of colon resection.~* Diverticulitis, symptomatic diverticulosis.~* Active peptic ulcer disease.~* Proctitis (extent of inflammation \< 15 cm from the anus).~* Bleeding disorders~* Rectal therapy with any therapeutic enemas or suppositories with the exception of those required for endoscopy during the 10 days preceding the screening.~* Active or chronic infection(s) or malignancies.~* Known hypersensitivity to the active ingredient and excipients of the study drug~* Patients treated with L-Carnitine or its esters derivatives during the 3 months preceding the screening phase.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Propionyl-L-Carnitine (Type: EXPERIMENTAL): Modified release tablets containing 500 mg of propionyl-L-carnitine
- Placebo (Type: PLACEBO_COMPARATOR): Modified release tablets containing inert substances

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy